Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elacestrant and Exemestane in Pretreated HR+/HER2- Metastatic Breast Cancer
NCT07395336Phase 2Recruiting
- Sponsor
- European Institute of Oncology
- Start
- May 2026
- Primary completion
- Dec 2028
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
A Phase 2 trial of elacestrant in breast cancer, sponsored by European Institute of Oncology. Started May 2026; status: recruiting.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07395336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07395336.